Dermatitis News

CHICAGO — Isotretinoin can be a helpful addition to the toolbox for seborrheic dermatitis treatment, according to a study presented at the American Society for Dermatologic Surgery Annual Meeting.

New data showed delgocitinib cream maintained symptom relief and treatment success in adults with chronic hand eczema, LEO Pharma announced in a press release.

In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more.

Patients being treated for atopic dermatitis with dupilumab had good reproducibility with patch testing for allergic contact dermatitis, according to a study.

Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.

Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.

Treatment with roflumilast foam was associated with a significant improvement in quality of life for patients with seborrheic dermatitis, according to a poster presented at the Academy of Managed Care Pharmacy Nexus meeting.

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release.

In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more.

Tape strips that capture the molecular fingerprint of chronic hand eczema indicated broadly shared immune and barrier dysregulations among patients who have and who do not have atopic dermatitis, according to a study abstract.